期刊文献+

^(32)P-磷酸铬体外诱导人非小细胞肺癌A549细胞凋亡 被引量:2

Study on apoptosis of human non-small cell pulmonary carcinoma A549 cells induced by ^(32)P-chromium phosphates in vitro
原文传递
导出
摘要 目的 观察32 P 磷酸铬 ( 32 P胶体 )体外诱导人非小细胞肺癌 (NSCLC)A5 4 9细胞周期变化和发生细胞凋亡的现象 ,建立剂量 效应和时间 效应关系。方法 将32 P胶体加入A5 4 9细胞培养体系进行内照射 ,初始放射性浓度分别为 0 ,93,180 ,2 78,370和 4 6 3MBq L ,采用Giemsa染色、透射电镜、末端原位标记 (TUNEL)等方法进行凋亡细胞的形态学、超微病理、生化特征检测 ,应用流式细胞术定量检测细胞周期变化和细胞凋亡率。结果 A5 4 9细胞受照射后S期 +G2 M期细胞比率在 96h以内呈上升趋势 ,之后逐渐下降。A5 4 9细胞受照射后 72h左右出现兴奋性表现 ,96h起各受照组均检出凋亡 ,各剂量组在照射后 12 0h达到凋亡高峰。结论 在较低剂量范围内 ,32 P胶体内照射可以体外诱导人NSCLCA5 4 9发生 72h以后的迟发相凋亡 。 Objective To observe the phasic change and apoptosis of A549 non-small cell lung cancer cells induced by 32 P chromium phosphate in vitro ,and establish the dose-response and time-response relationship. Methods Internal irradiation was conducted by adding 32 P colloid into A549 cell culture system.The initial radioactivities were 0,93,180,278,370,463 MBq/L,respectively.Giemsa stain,transmission electron microscopy and TUNEL were used in assessing morphologic,ultra structural pathologic and biochemical characteristics,and the phasic changes and apoptotic rates of cells were studied by flow cytometry. Results After irradiation of A549 cells,the cell ratio of S+G 2 M phase tended to increase within 96 h,then decreased gradually.At 72 h after irradiation the A549 cells showed excited manifestation,and in each irradiation group apoptosis began from 96 h of irradiation,and attained the peak at 120 h. Conclusion In the lower dosagerange, 32 P internal irradiation may induce human NSCLC A549 cells to present delayed onset of apoptosis,and the rate of cell apoptosis is positively correlated to the initial radioactivity concentration.
出处 《中华放射医学与防护杂志》 CAS CSCD 北大核心 2004年第3期233-236,共4页 Chinese Journal of Radiological Medicine and Protection
基金 江苏省科委应用基础基金资助项目(BJ2 0 0 0 0 0 4) 江苏省卫生厅科研基金资助项目(H2 0 0 117)
关键词 ^32P-磷酸铬 体外诱导 非小细胞肺癌 A549细胞 细胞凋亡 NSCLC 细胞周期 Tumor Non-small cell lung cancer Apoptosis Radioactive nucleotied 32 P chromium phosphate
  • 相关文献

参考文献2

二级参考文献12

  • 1Fareh J,Circulation,1999年,99卷,1477页
  • 2Li P F,Circulation,1997年,96卷,3602页
  • 3Elizabeth Y,Blood,1996年,88卷,386页
  • 4Han D K M,Am J Pathol,1995年,147卷,267页
  • 5Sheppard R, Eisenberg MJ. Intracoronary radiotherapy for restenosis. N Engl J Med, 2001, 344: 295-297.
  • 6Sapirstein W, Zuckerman B. FDA approval of coronary-artery brachytherapy. N Engl J Med, 2001, 344: 297-299.
  • 7Verin V, Poppwski Y, Urban P, et al. Intra-arterial beta irradiation prevents neointimal hyperplasia in a hypercholesterolemic rabbit restenosis model. Circulation, 1995, 92: 2284-2290.
  • 8Brenner DJ, Miller RC, Hall EJ. The radiobiology of intravascular irradiation. Int Radiat Oncol Biol Phys, 1996, 36: 805-810.
  • 9Nath R, Amols H, Coffey C, et al. Intravascular brachytherapy physics:report of the AAPM Radiation Therapy Committee Task Group No. 60.American Association of Physicists in Medicine. Med Phys, 1999, 26:119-152.
  • 10Waksman R, Ajani AE, White RI, et al. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis. Circulation, 2001, 103: 2332-2335.

共引文献9

同被引文献12

  • 1Tabernero J, Climent M A, Lluch A, et al. Amulticentre, randomised phase II study of weekly or S-weekly docetaxel in patients with metastatic breast cancer[J]. Ann Oncol, 2004, 15(9): 1358-1365.
  • 2Ishikawa T, Shimizu S, Inaba M, et al. A Multieenter phase Ⅱ study of docetaxel 60 mg/m^2 first-line chemotherapy in patients with advanced or recurrent nreast cancer[J]. Breast Cancer,2004, 11(4): 374-379.
  • 3Bonneterre J, Dieras V, Tubiana-Hulin M, et al. Phase Ⅱ multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer[J]. Br J Cancer,2004, 91(8): 1466-1471.
  • 4Mavroudis D, Malamos N, Polyzos A, et al. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenterphase II study[J]. Oncology,2004, 67(3-4): 250-256.
  • 5Gomez-Bernal A, Cruz J J, Olaverri A, et al. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer[J]. Anticancer Drugs, 2005,16 (1) : 77 - 82.
  • 6Park S H, Cho E K, Bang S M, et al. Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment[J]. BMC Cancer,2005,22(5):21-21.
  • 7Wolff A C, Davidson N E. Primary systemic therapy in operable breast cancer[J]. J Clin Oncol,2000,18(7) .1558-1569.
  • 8Diaz J F, Andreu J M. Assembly of purified GDP-tubulin into microtubules inducedby taxol and taxotere: reversibility, ligand stoichiometry, and competition [J]. Biochemistry, 1993, 32(11) : 2747- 2755.
  • 9Green D R, Reed J. Mitochondria and apoptosis[J]. Science,1998,281 (5381):1309-1312.
  • 10石银珍.细胞凋亡与乳腺癌的发生和治疗研究进展[J].中国肿瘤临床与康复,2001,8(5):117-118. 被引量:2

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部